New Drug Application for hyperphosphatemia in chronic kidney disease patients on dialysis under review by the FDA with a ...

Oxylanthanum carbonate is a next-generation lanthanum-based phosphate binding agent utilizing proprietary nanoparticle technology being developed for the treatment of hyperphosphatemia in patients ...